Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Operating activities    
Net loss $ (7,454,048) $ (3,882,847)
Adjustments to reconcile net loss provided by (used in) to net cash used in operating activities:    
Depreciation and amortization 1,098,478 1,023,040
Stock-based compensation 596,693 242,824
Deferred taxes 5,941 15,913
Amortization of inventory fair value associated with acquisition of TRx and Avadel 22,603 45,450
Non-cash interest expense 0 105,451
Change in fair value of warrant liability and unit purchase option liability 47,577 23,251
Change in fair value of contingent consideration and long-term royalty obligation 180,402 262,769
Other 21,412 0
Changes in assets and liabilities:    
Accounts receivable, net 439,159 104,671
Other receivables (62,014) 371,663
Inventory, net 41,195 (554,445)
Prepaid expenses and other assets 281,051 (71,085)
Escrowed cash receivable 0 (2,065)
Accounts payable (196,671) 1,866,960
Income taxes payable (217,608) 7,400
Accrued expenses and other liabilities 2,074,278 160,627
Net cash used in operating activities (3,121,552) (280,423)
Investing activities    
Acquisition of business 0 (1)
Purchase of property and equipment (165,969) (19,224)
Net cash used in investing activities (165,969) (19,225)
Financing activities    
Proceeds from exercise of stock options and warrants 94,177 363,390
Proceeds from underwritten public offering, net 8,975,960 0
Payment of contingent consideration (228,678) 0
Payment of long-term debt (24,342) 0
Net cash provided by financing activities 8,817,117 363,390
Increase in cash, cash equivalents and restricted cash 5,529,596 63,742
Cash, cash equivalents, and restricted cash at beginning of period 10,746,756 2,605,499
Cash, cash equivalents, and restricted cash at end of period 16,276,352 2,669,241
Supplemental disclosures of cash flow information    
Cash paid for interest 262,500 44,003
Cash paid for taxes 378,025 0
Supplemental disclosures of non-cash activities    
Leased asset obtained in exchange for new operating lease liability 743,025  
Debt assumed in Avadel Pediatric Products acquisition 0 (15,075,000)
Cash and cash equivalents 16,121,388 2,523,927
Restricted cash, current 77,846 13,955
Restricted cash, non-current $ 77,118 $ 131,359